WGS — GeneDx Holdings Corp.

Summary of GeneDx Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $114.4 million, up 11% year-over-year, exceeding guidance.
• Exome and Genome Revenue: $100.3 million, up 17%.
• Volume: 30,785 tests conducted, representing a 32% year-over-year growth.
• Gross Margin: 70%, an increase from 69% in Q1.
• Profitability: Returned to profitability with adjusted net income of $0.4 million, an $8.6 million improvement from Q1.
• Blended Average Reimbursement Rate (ARR): $3,258 per test, flat quarter-over-quarter.

2. Strategic Updates and Business Highlights

• Record Testing Volume: Achieved over 30,000 tests in Q2, reflecting strong demand.
• Market Development Strategy: Focused on expanding payer coverage, with Carelon increasing commercial genome coverage from 47% to 87% in one quarter.
• Operational Improvements: Emphasis on optimizing unit economics, enhancing revenue cycle management (RCM), and diversifying sales channels, particularly in general pediatrics.
• New Leadership: Mark Gardner joined as President, bringing experience to enhance operational efficiency and revenue generation.

3. Forward Guidance and Outlook

• Full Year 2026 Guidance: Reaffirmed revenue expectations of $475 million to $490 million, with continued volume growth of at least 30% and revenue growth of at least 20%.
• Q3 Guidance: Expected revenues between $122 million and $124 million, with exome and genome revenue of $110 million to $112 million.
• Long-term Outlook: Anticipated improvements in collection rates and operational efficiencies expected to drive revenue growth in 2027 and beyond.

4. Bad News, Challenges, or Points of Concern

• Collection Rates: Current outpatient genome collection rate at 32%, down from 43% year-over-year, indicating challenges in reimbursement despite increased coverage.
• Operational Lag: There is a natural lag between improvements in payer coverage and actual revenue realization, which may affect near-term performance.
• Competitive Pressures: While GeneDx maintains a strong market position, the shift towards genome testing may intensify competition, necessitating continuous innovation and service quality.

5. Notable Q&A Insights

• Pacing of Collection Rates: Q3 collection rates expected to remain flat, with meaningful improvements anticipated in Q4 as operational changes take effect.
• Mix Management: The company is strategically managing the mix of exome and genome tests to optimize revenue, with reflex testing showing strong growth.
• Sales Force Productivity: New sales representatives are expected to ramp up productivity, contributing to growth in emerging markets, particularly in general pediatrics.
• Carelon and Medi-Cal Opportunities: Significant potential for revenue growth from expanded coverage, but realization may take time due to operationalization delays.

This summary encapsulates the key points from the earnings call, highlighting GeneDx's financial performance, strategic initiatives, future outlook, and challenges faced in the current market environment.